Smith & Nephew plc vs Sony Group Corp — how do they compare? Smith & Nephew plc trades at $27.24 (market cap $11.10B), while Sony Group Corp trades at $24.12 (market cap $136.87B). The key difference: Sony Group Corp is far larger — about 12.3× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 121 Days and Sony Group Corp for 96 Days on average.
| SNN | SONY | |
|---|---|---|
Market Cap | $11.10B | $136.87B |
Volume | 1,051,703 | 5,364,503 |
Sector | Health | Technology |
52-Week High | $37.17 | $30.26 |
52-Week Low | $26.42 | $19.32 |
Typical Hold Time | 121 Days | 96 Days |
Enterprise Value | $14.13B | $134.77B |
Dividend Yield | 2.95% | 0.66% |
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Sony trades at $24.12, up 2.55% today, with a bullish technical outlook supported by moving averages. The company reported mixed quarterly results with two beats and one miss, while full-year 2025 showed strong revenue of $12.96T and net income of $1.14T. Analyst sentiment remains positive with 11 buy ratings and no sell recommendations, though 2026 projections indicate potential profitability challenges with negative net income margins.
Sony presents a compelling value opportunity with reasonable valuation metrics (P/E 20.34, P/S 1.79) and strong cash flow generation, but faces headwinds from projected 2026 profitability decline. The entertainment and technology conglomerate benefits from diverse revenue streams and intellectual property strength, though investors should monitor execution risks amid competitive pressures and macroeconomic uncertainty.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →